Maricann Group Inc.
CSE : MARI
CSE : MARI.CN
CNSX : MARI
OTCQB : MRRCF
FRANKFURT : 75M

Maricann Group Inc.

October 03, 2017 17:00 ET

Maricann Announces Appointment of New Chief Financial Officer

TORONTO, ONTARIO--(Marketwired - Oct. 3, 2017) - Maricann Group Inc. (CSE:MARI)(CSE:MARI.CN)(CNSX:MARI)(OTCQB:MRRCF)(FRANKFURT:75M) ("Maricann" or the "Company") is pleased to announce the appointment of Scott Langille as the Company's Chief Financial Officer effective October 2, 2017, subject to regulatory approval.

Mr. Langille has over 30 years of experience in the pharmaceutical industry in both Canada and the United States. He was formerly Chief Financial Officer of Tribute Pharmaceuticals Canada Inc. ("Tribute Pharmaceuticals"), which was sold to Pozen Inc. in February 2016 for US$160 million to form Aralez Pharmaceuticals Inc. Mr. Langille also served as Chief Financial Officer of Virexx Medical Corp., a biotechnology company, Director, Corporate Finance at Biovail Corporation, Director of Finance at Biovail Pharmaceuticals Canada, Biovail's sales and marketing division in Canada, as well as Vice President at Biovail Pharmaceuticals Inc., Biovail's sales and marketing division in the United States. Other prior management positions include Director, Finance at AltiMed Pharmaceuticals Company and Controller at Zimmer Canada. Mr. Langille has a professional accounting designation and an MBA from the University of Toronto.

"We are delighted to have Scott Langille join Maricann in the capacity of CFO. Scott's extensive experience in strategic planning, business development, corporate financing and strong financial oversight make him a welcome member of the executive team, as we move forward with Maricann's global initiatives," said Ben Ward, CEO of Maricann.

For more information about Maricann, please visit our website at www.maricann.ca.

About Maricann Group Inc.

Maricann is a vertically integrated producer and distributor of marijuana for medical purposes. The company was founded in 2013 and is based in Toronto with a facility in Langton, Ontario, where it operates a medicinal cannabis cultivation, extraction and distribution business under federal licence from the Government of Canada. Maricann, which has federal licences to cultivate, process and distribute cannabis, services a patient base with more than 8,000 total registered patients since inception. Maricann is currently undertaking an expansion of its cultivation and support facilities in Canada in a fully funded 217,000 sq. ft. (20,159 sq. m) build out, to support existing and future patient growth.

Forward Looking Information

Certain statements in this document contain forward-looking statements which can be identified by the use of forward-looking terminology such as "believes", "expects", "may", "desires", "will", "should", "projects", "estimates", "contemplates", "anticipates", "intends", or any negative such as "does not believe" or other variations thereof or comparable terminology. No assurance can be given that potential future results or circumstances described in the forward-looking statements will be achieved or will occur. By their nature, these forward-looking statements, necessarily involve risks and uncertainties, including those discussed herein that could cause actual results to significantly differ from those contemplated by these forward-looking statements. Such statements reflect the view of the Company with respect to future events, and are based on information currently available to the Company and on assumptions, which it considers reasonable. Management cautions readers that the assumptions relative to the future events, several of which are beyond Management's control, could prove to be incorrect, given that they are subject to certain risk and uncertainties, and that actual results may differ materially from those projected. Factors which could cause results or events to differ from current expectations include, among other things: fluctuations in operating results; the impact of general economic, industry and market conditions; the ability to recruit and retain qualified employees; fluctuations in cash flow; increased levels of outstanding debt and obligations under a capital lease; expectations regarding market demand for particular products and the dependence on new product development; the impact of market change; and the impact of price and product competition. Management disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. The reader is cautioned not to place undue reliance on forward-looking information.

Contact Information

  • Investor Relations:
    Shawn Alexander
    VP Investor Relations
    289-288-6284
    salexander@maricann.ca

    Corporate Headquarters (Canada)
    Maricann Group Inc. (Toronto)
    845 Harrington Court, Unit 3
    Burlington Ontario L7N 3P3
    Canada
    289-288-6274

    European Headquarters (Germany)
    Maricann GmbH
    Thierschstrasse 3, 80538 Munchen, Deutschland